| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, 113-8655, Japan [T. Take., T. Taki, N. S., Y. H.]; Department of Pediatrics, Shimane Medical University, Shimane 693-8501, Japan [T. Take.]; and Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Aomori 036-8562, Japan [E. I., J. K., K. T.]
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
NUP98 is a Mr 98,000 component of NPC located on the nucleoplasmic side of the NPC (12) . NUP98 consists of an FG repeat motif, Gle2p-binding-like motif, and ribonucleoprotein-binding motif (12) . NUP98 functions as one of several docking NUPs for the transport of RNA and protein between the nucleus and cytoplasm; it is an essential component of multiple RNA export pathways (12 , 13) .
The homeobox genes have a conserved homeodomain sequence discovered in genes of the Drosophila melanogaster and encode transcription factors that act as morphogenetic regulatory molecules (14) . The homeobox genes act in the patterning of the development of many segmental and axial structures in several organisms (14) . The 39 human homeobox-containing genes (HOX genes) are organized in four clusters (HOX-A, B, C, and D). The HOX gene expression in hematopoietic cells varies, depending on differences in the lineage and maturation of the cells (15) .
To our knowledge, only five patients with t(2;11)(q31;p15) have been reported previously (7 , 16, 17, 18, 19) . These patients were diagnosed as having myeloid malignancies, including three with AML (7 , 18 , 19) and two with myelodysplastic syndrome (MDS; Refs. 16 , 17 ). NUP98-HOXD13 fusion transcripts were found in the three AML patients with the translocation. We report here a novel partner gene of NUP98, HOXD11, in a de novo pediatric patient with t(2;11)(q31;p15)-AML. We also report a specific expression pattern of the HOXD11 and HOXD13 genes.
| Materials and Methods |
|---|
|
|
|---|
cDNA Panhandle PCR.
To detect the 3' unknown gene fused to the 5' NUP98 gene, we adapted the cDNA panhandle PCR strategy with some modification, which was reported as a method to detect MLL fusion partner genes (Ref. 20
; Fig. 2A
). Total RNA was extracted from the patients leukemic cells using the acid guanidine thiocyanate-phenol chloroform method (21)
. Four µg of total RNA was reverse-transcribed to first-strand cDNAs using oligonucleotides with the known NUP98 coding sequence from the predicted breakpoint region at the 5' ends and random hexamers at the 3' ends (5'-CTGGACAGGCATCTTTGTTTGGGAACAACCNNNNNN-3'), using a cDNA synthesis kit (Amersham Pharmacia Biotech, Buckinghamshire, England). To test for the presence of amplifiable RNA, ß-actin was amplified using the same cDNA by RT-PCR. To generate sense second-strand templates for panhandle PCR, 2 µl of the cDNA solution was added to a 98-µl mixture containing 2 units of rTth DNA polymerase, 200 µM each: dNTP, 3.3x buffer, MgCl2 1 mM (Applied Biosystems, Foster, CA), and 40 pmol of NUP98-1S (5'-GGGACTCTTGGAACTGGGCTT-3'). PCR amplification was performed with this mixture using a DNA thermal-cycler (Applied Biosystems) under the following conditions: preheating at 94°C for 1 min, 25 cycles of denaturation for 15 s at 94°C, and annealing and extension for 10 min at 68°C, with a final extension of 10 min at 72°C. To make intrastrand annealing and polymerase extension, NUP98-1S extension was achieved by denaturing at 94°C for 9 min followed by 1 cycle at 94°C for 1 min and 72°C for 8 min. As a result, stem-loop templates contained the fusion point of the chimeric transcript in the loop. Using NUP98-2S (5'-CCTCTTGGTACAGGAGCCTTT-3') between the NUP98 sequence that was complementary to the ligated oligonucleotide and the breakpoint region, RT-PCR was performed with mixtures (50 µl) containing 12.5 pmol of NUP98 primer 1 and 2, 200 µM each: dNTP and 10x buffer. After initial denaturation at 94°C for 9 min, 40 cycles at 94°C for 1 min, at 55°C for 1 min, and at 72°C for 3 min, were used, followed by a final elongation at 72°C for 7 min. Nested RT-PCR was performed with the same conditions and 1 µl of the initial RT-PCR. The primers for nested RT-PCR were NUP98-3S (5'-GCAGGATTTGGAACAGCTCTTGGT-3') and NUP98-4S (5'-ACTACGACAGCCACTTTGGG-3').
|
Southern Blot Analysis.
High-molecular-weight DNA was extracted from bone marrow cells of the patients by proteinase K digestion and phenol/chloroform extraction (22)
. Ten µg of DNA were digested with EcoRI, subjected to electrophoresis on 0.7% agarose gels, and transferred to cDNA probes that were 32P-labeled by the random hexamer method (21)
. Probes used were 837 bp NUP98 cDNA fragments [nucleotide (nt)1213 to 2049; GenBank accession no. U41815] and 316 bp HOXD11 cDNA fragments (nt 527 to nt 842; GenBank accession no. XM002543).
RT-PCR.
The same conditions as for the panhandle PCR were used for RNA extraction and cDNA synthesis. One µl of the cDNA solution was amplified by PCR in a total volume of 20 µl with 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.001% (w/v) gelatin, 200 mM each dNTP, 2.5 units of Taq polymerase (Applied Biosystems), and 20 pmol of each primer (21)
. NUP98-5S (5'-TTTGGTGCTGTTGGTTCGAC-3') and HOXD11-1AS (5'-GGAACCAGATTTTGACTTGCCG-3') were used to confirm the NUP98-HOXD11 fusion transcripts. HOXD13-1AS (5'-ACTCTCTTCTTCCTCCCTCTTC-3') was used to confirm the NUP98-HOXD13 fusion transcripts. PCR amplification was performed under the following conditions: preheating at 94°C for 9 min plus 40 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 55°C, and extension for 1 min at 72°C, with a final extension of 7 min at 72°C. Also, expression of the HOXD11 and HOXD13 genes was examined by RT-PCR. The primers used for RT-PCR were HOXD11-1S (5'-TCCTCTTCTGCCGTTGTAG-3'), HOXD11-1AS, HOXD13-1S (5'-GACTTCAACTCTCTCGGATGCT-3') and HOXD13-1AS. Amplified products were electrophoresed on a 3% agarose gel, stained with ethidium bromide, and photographed with a polaroid camera under UV light.
Cell Lines.
To analyze the expression of the HOXD11 and HOXD13 genes, we used 64 cell lines as follows (22)
: 12 B-precursor ALL cell lines without BCR-ABL transcripts (UTP-L20, P30/OHK, LC4-1, NALM-26, THP-4, THP-5, THP-7, THP-8, RS4;11, KOCL-33, KOCL-44, KOCL-45); 5 B-precursor ALL cell lines with BCR-ABL transcripts (BV173, OM9;22, NALM-20, NALM-24, UTP-2); 10 B-ALL cell lines (BALM-1, BALM-6, BALM-9, BALM-13, BALM-14, BJAB, DAUDI, RAJI, RAMOS, BAL-KH); 10 T-ALL cell lines (RPMI-8402, MOLT-14, KOPT-KI, THP-6, PEER, JURKAT, HSB-2, HPB-ALL, L-SAK, L-SMY); 9 AML cell lines (YNH-1, ML-1, KASUMI-3, KG-1, P39/TSU, inv-3, SN-1, NB4, HEL); 6 AMOL cell lines (THP-1, IMS/M1, CTS, P31/FUJ, MOLM-13, KOCL-48); 5 CML cell lines (MOLM-1, MOLM-7, TS9;22, SS9;22, K-562); 2 AMKL cell lines (CMS, CMY); and 5 EBV-B cell lines derived from normal healthy adult peripheral lymphocytes. We also examined MNCs from the peripheral blood of 5 normal healthy adults.
| Results and Discussion |
|---|
|
|
|---|
|
RT-PCR analysis using NUP98-5S and HOXD11-1AS revealed two types of NUP98-HOXD11 in-frame fusion transcripts, one containing exon 12 of the NUP98 gene (up to nt 1552) fused to exon 2 of the HOXD11 gene, and the other containing exon 11 of the NUP98 gene (up to nt 1411) fused to exon 2 of the HOXD11 gene (Fig. 2, B and C)
. However, no reciprocal fusion transcripts (HOXD11-NUP98) were detected (Fig. 2B)
.
We performed RT-PCR analysis in 61 leukemic cell lines, 5 EBV-B cell lines and 5 normal MNCs. Expression of the HOXD11 gene was found in 4 (80.0%) of 5 CML cell lines, 6 (50.0%) of 12 BCR-ABL-negative B-precursor ALL cell lines, 3 (60.0%) of 5 BCR-ABL-positive B-precursor ALL cell lines, 2 (20.0%) of 10 B-ALL cell lines, 3 (30.0%) of 10 T-ALL cell lines, 2 (33.3%) of 6 AMOL cell lines, 2 (22.2%) of 9 AML cell lines, 1 (20.0%) of 5 EBV-B cell lines, and 2 (40.0%) of 5 normal MNCs (Table 1
; Fig. 3B
). No expression was detected in two AMKL cell lines examined.
|
|
The HOXD13 gene has been identified as a fusion partner of the NUP98 gene in t(2;11)(q31;p15)-AML (7) . In the present study, we isolated a novel chimeric transcript, NUP98-HOXD11, in a de novo pediatric patient with AML (M4) having t(2;11)(q31;p15), which was the same translocation breakpoint as NUP98-HOXD13. Recent molecular analysis has shown that different genes in the same chromosomal region were identified as fusion partners of MLL, such as MLL-ELL, MLL-ENL, and MLL-EEN in t(11;19)(q23;p13) (2) . Our result suggests that it is difficult to predict the fusion partner of the NUP98 gene in t(2;11)(q31;p15) only by cytogenetics.
Two NUP98-HOXD11 fusion transcripts are predicted to encode a protein of 499 amino acids and 547 amino acids, respectively. Both proteins are caused by the alternative splicing consist of an NH2-terminal FG repeat motif and COOH-terminal homeodomain. The difference between these chimeric proteins is attributable to the number of FG peptide repeats. Both the NH2-terminal FG repeat motif and COOH-terminal homeodomain are retained in the NUP98-HOXA9, NUP98-HOXD13, and NUP98-PMX1 fusion proteins. Mice transplanted with bone marrow cells expressing NUP98-HOXA9 through retroviral transduction acquire a myeloproliferative disease and eventually succumb to AML (23) . This suggests that NUP98-HOXD11 could use a similar mechanism that leads to leukemogenesis.
HOXD11, a human homologue of mouse Hoxd11, is a homeobox gene. The function of the HOXD11 gene in hematopoiesis remains unclear, although other HOX genes, such as the HOXC cluster and HOXA9, were reported to be important in hematopoiesis (15 , 24) . The Hoxd11 gene contributes to the development of front legs in mice (25) .
Expression of the HOX genes in hematopoietic cell lines results in differences in lineage commitment and maturation of these cells (15) ; for example, expression of the HOXA10 gene was restricted to myelomonocytic cell lines (26) and expression of the HOXC4 gene was predominant in lymphoid cell lines (27) . In HOXD cluster genes, it was reported that expression of the HOXD3 gene was found in HEL and K562 but not in HL-60 (28) , whereas expression of the HOXD13 gene was found in HEL, Kasumi-1, and MOLT-4 but not in U937 (18) . Our study revealed that expression of the HOXD11 gene was significantly higher in BCR-ABL-positive leukemic cell lines than in BCR-ABL-negative leukemic cell lines (P = 0.028). The reason for high expression of the HOXD11 gene in BCR-ABL-positive leukemic cell lines is unclear. Expression of the HOXD11 gene was found more frequently in BCR-ABL-negative B-precursor ALL cell lines and CML cell lines than in other cell lines, but these differences were not significant statistically. Notably, expression of the HOXD13 gene was significantly higher in myeloid cell lines than in lymphoid cell lines (P < 0.0001). Overexpression of Hoxb8 with interleukin-3, Hoxa10, Hoxb3, and Hoxa9, with Meis1 in murine hematopoietic cells was reported to lead to the development of AML (29, 30, 31, 32) . Our results, combined with previous reports, suggest that the expression of one or more HOX genes, including the HOXD11 and HOXD13, is associated with the development or proliferation of leukemia.
In conclusion, our study revealed that t(2;11)(q31;p15) was not a single chromosomal abnormality: it results from not only the NUP98-HOXD13 but also the NUP98-HOXD11 fusion gene. Although expression of the HOXD11 and HOXD13 genes in leukemic cell lines was different, the NUP98-HOXD fusion genes encode similar fusion proteins, suggesting that the NUP98-HOXD11 as well as NUP98-HOXD13 fusion protein play a role in leukemogenesis through similar mechanism. To clarify the roles of NUP98-HOXD11 and NUP98-HOXD13 fusion proteins in leukemogenesis, further functional analysis of both fusion proteins and accumulation of cases with t(2;11) is needed.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan, a Grant-in-Aid for Scientific Research on Priority Areas, and Grant-in-Aid for Scientific Research (B) and (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work also was supported by Kawano Medical Foundation. ![]()
2 To whom requests for reprints should be addressed, at Department of Pediatrics, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Phone: 81-3-3815-5411, extension 33452; Fax: 81-3-3816-4108; E-mail: hayashiy-tky{at}umin.ac.jp ![]()
3 The abbreviations used are: AML, acute myeloid leukemia; RT, reverse transcription; NUP, nucleoporin; ALL, acute lymphoblastic leukemia; FG, phenylalanine-glycine; NPC, nuclear pore complex; MNC, mononuclear cell; CML, chronic myelogenous leukemia; AMKL, acute megakaryoblastic leukemia; AMOL, acute monocystic leukemia; EBV-B, EBV-transformed B lymphocyte; HOX, homeobox. ![]()
Received 4/27/01. Accepted 11/ 5/01.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y.-W. Lin, C. Slape, Z. Zhang, and P. D. Aplan NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia Blood, July 1, 2005; 106(1): 287 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iwasaki, T. Kuwata, Y. Yamazaki, N. A. Jenkins, N. G. Copeland, M. Osato, Y. Ito, E. Kroon, G. Sauvageau, and T. Nakamura Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model Blood, January 15, 2005; 105(2): 784 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Gurevich, P. D. Aplan, and R. K. Humphries NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation Blood, August 15, 2004; 104(4): 1127 - 1136. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ghannam, A. Takeda, T. Camarata, M. A. Moore, A. Viale, and N. R. Yaseen The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid Cells J. Biol. Chem., January 9, 2004; 279(2): 866 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ferrando, S. A. Armstrong, D. S. Neuberg, S. E. Sallan, L. B. Silverman, S. J. Korsmeyer, and A. T. Look Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation Blood, July 1, 2003; 102(1): 262 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Lahortiga, J. L. Vizmanos, X. Agirre, I. Vazquez, J. C. Cigudosa, M. J. Larrayoz, F. Sala, A. Gorosquieta, K. Perez-Equiza, M. J. Calasanz, et al. NUP98 Is Fused to Adducin 3 in a Patient with T-Cell Acute Lymphoblastic Leukemia and Myeloid Markers, with a New Translocation t(10;11)(q25;p15) Cancer Res., June 15, 2003; 63(12): 3079 - 3083. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pineault, C. Buske, M. Feuring-Buske, C. Abramovich, P. Rosten, D. E. Hogge, P. D. Aplan, and R. K. Humphries Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1 Blood, June 1, 2003; 101(11): 4529 - 4538. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Taketani, T. Taki, N. Shibuya, A. Kikuchi, R. Hanada, and Y. Hayashi Novel NUP98-HOXC11 Fusion Gene Resulted from a Chromosomal Break within Exon 1 of HOXC11 in Acute Myeloid Leukemia with t(11;12)(p15;q13) Cancer Res., August 15, 2002; 62(16): 4571 - 4574. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ono, T. Taki, T. Taketani, M. Taniwaki, H. Kobayashi, and Y. Hayashi LCX, Leukemia-associated Protein with a CXXC Domain, Is Fused to MLL in Acute Myeloid Leukemia with Trilineage Dysplasia Having t(10;11)(q22;q23) Cancer Res., July 15, 2002; 62(14): 4075 - 4080. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |